Alemtuzumab
DefinitionThis section has been translated automatically.
Genetically engineered, humanized, monoclonal IgG1 Kappa antibody that specifically binds to the 21 to 28 kDa glycoprotein CD52 on the cell surface of lymphocytes. CD52 is a surface antigen expressed by B and T lymphocytes. The antibody is produced in a suspension culture of mammalian cells (ovarian cells of the Chinese hamster).
IndicationThis section has been translated automatically.
Chronic lymphatic leukemia (CLL), Sézary syndrome. Indication is given in the absence of or insufficient improvement on the administration of alkylants and nucleoside analogues such as Fludarabine. Alemtuzumab shows a good response rate in pre-treated patients and may prolong the mean survival time. However, it does not offer a curative therapeutic approach, just as conventional cytostatic drugs do not.
Dosage and method of useThis section has been translated automatically.
Maintenance doses in CLL have been reported as 30 mg 3 times/week. The mean therapy time is 12 months. In Sézary syndrome, a "low-dose" therapy concept with 3 times/week 15 mg has been successfully applied (due to the still high rate of infection complications, a dosage of 3 times/week 10 mg is recommended).
Undesirable effectsThis section has been translated automatically.
Severe hemologic toxicity (grade 3-4 cytopenia up to 45%), increased risk of infectious complications (bacterial sepsis).
PreparationsThis section has been translated automatically.
MabCampath
LiteratureThis section has been translated automatically.
- Bernengo MG et al Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunological findings in 14 patients. Haematologica 92: 785-792